Your browser doesn't support javascript.
loading
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis.
Raglow, Zoe; Surie, Diya; Chappell, James D; Zhu, Yuwei; Martin, Emily T; Kwon, Jennie H; Frosch, Anne E; Mohamed, Amira; Gilbert, Julie; Bendall, Emily E; Bahr, Auden; Halasa, Natasha; Talbot, H Keipp; Grijalva, Carlos G; Baughman, Adrienne; Womack, Kelsey N; Johnson, Cassandra; Swan, Sydney A; Koumans, Emilia; McMorrow, Meredith L; Harcourt, Jennifer L; Atherton, Lydia J; Burroughs, Ashley; Thornburg, Natalie J; Self, Wesley H; Lauring, Adam S.
Affiliation
  • Raglow Z; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Surie D; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Chappell JD; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zhu Y; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Martin ET; School of Public Health, University of Michigan, Ann Arbor, MI, USA.
  • Kwon JH; Department of Medicine, Washington University, St Louis, MO, USA.
  • Frosch AE; Department of Medicine, Hennepin County Medical Center, Minneapolis, MN, USA.
  • Mohamed A; Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Gilbert J; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Bendall EE; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Bahr A; Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
  • Halasa N; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Talbot HK; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Grijalva CG; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Baughman A; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Womack KN; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Johnson C; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Swan SA; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Koumans E; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • McMorrow ML; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Harcourt JL; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Atherton LJ; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Burroughs A; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Thornburg NJ; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Self WH; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Lauring AS; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA. Electronic address: alauring@med.umich.edu.
Lancet Microbe ; 5(3): e235-e246, 2024 03.
Article in En | MEDLINE | ID: mdl-38286131
ABSTRACT

BACKGROUND:

Prolonged SARS-CoV-2 infections in people who are immunocompromised might predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection have not been systematically investigated. We aimed to assess risk factors for prolonged SARS-CoV-2 infection and associated intrahost evolution.

METHODS:

In this multicentre, prospective analysis, participants were enrolled at five US medical centres. Eligible patients were aged 18 years or older, were SARS-CoV-2-positive in the previous 14 days, and had a moderately or severely immunocompromising condition or treatment. Nasal specimens were tested by real-time RT-PCR every 2-4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection.

FINDINGS:

From April 11, 2022, to Oct 1, 2022, 156 patients began the enrolment process, of whom 150 were enrolled and included in the analyses. Participants had B-cell malignancy or anti-B-cell therapy (n=18), solid organ transplantation or haematopoietic stem-cell transplantation (HSCT; n=59), AIDS (n=5), non-B-cell malignancy (n=23), and autoimmune or autoinflammatory conditions (n=45). 38 (25%) participants were real-time RT-PCR-positive and 12 (8%) were culture-positive 21 days or longer after initial SARS-CoV-2 detection or illness onset. Compared with the group with autoimmune or autoinflammatory conditions, patients with B-cell dysfunction (adjusted hazard ratio 0·32 [95% CI 0·15-0·64]), solid organ transplantation or HSCT (0·60 [0·38-0·94]), and AIDS (0·28 [0·08-1·00]) had longer duration of infection, defined as time to last positive real-time RT-PCR test. There was no significant difference in the non-B-cell malignancy group (0·58 [0·31-1·09]). Consensus de novo spike mutations were identified in five individuals who were real-time RT-PCR-positive longer than 56 days; 14 (61%) of 23 were in the receptor-binding domain. Mutations shared by multiple individuals were rare (<5%) in global circulation.

INTERPRETATION:

In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance.

FUNDING:

US Centers for Disease Control and Prevention.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acquired Immunodeficiency Syndrome / COVID-19 / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Lancet Microbe Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acquired Immunodeficiency Syndrome / COVID-19 / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Lancet Microbe Year: 2024 Document type: Article Affiliation country: Estados Unidos